TCR2 Therapeutics (TCRR) Collaborates with Bristol Myers Squibb to Evaluate Gavo-cel in Combination with Opdivo and Yervoy in Mesothelin-Expressing Solid Tumors

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. INTC
2. DSX
3. GNK
4. III
5. TTEC
6. DAL
7. AWK
8. SPCX
9. AMIX
10. Z

Go back to TCR2 Therapeutics (TCRR) Collaborates with Bristol Myers Squibb to Evaluate Gavo-cel in Combination with Opdivo and Yervoy in Mesothelin-Expressing Solid Tumors

Bristol-Myers Squibb (BMY) Tops Q3 EPS by 6c

October 27, 2021 7:00 AM EDT

Bristol-Myers Squibb (NYSE: BMY) reported Q3 EPS of $2.00, $0.06 better than the analyst estimate of $1.94. Revenue for the quarter came in at $11.62 billion versus the consensus estimate of $11.64 billion.

GUIDANCE:

Bristol-Myers Squibb sees FY2021 EPS of $7.40-$7.55, versus the consensus of... More

TCR2 Therapeutics (TCRR) PT Lowered to $20 at Mizuho Securities

October 21, 2021 6:39 AM EDT

Mizuho Securities analyst Mara Goldstein lowered the price target on TCR2 Therapeutics (NASDAQ: TCRR) to $20.00 (from $51.00) while maintaining a Buy rating.... More